ALVO•prnewswire•
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Summary
ALVO Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, Dec. 2, 2025 /PRNewswire/ -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 3, 2025 by prnewswire